To assess the optimal target range of the automatic FiO2 function by maintaining the same mean, and narrowing the upper and lower limits of the target range.
ID
Source
Brief title
Condition
- Other condition
Synonym
Health condition
Hypoxie en hyperoxie bij prematuriteit
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
The main outcome parameter will be the proportion of time spent within the
saturation ranges used in clinical setting, being 86-94%.
Secondary outcome
Secondary outcomes will be the proportion of time being in hypoxia or
hyperoxemia, the distribution of SpO2 between the different periods, and the
duration of episodes with hypoxia or hyperoxemia.
Background summary
Both hypoxia and hyperoxia can lead to organ damage in preterm infants. For
this reason the transcutaneously measured oxygen saturation (SpO2) is kept
within a range between 86% and 95%. Hypoxia is mainly caused by immature or
impaired control of breathing (apnea) and/or a compromised lung function.
Hypoxia is often treated with supplemental oxygen, which is manually adjusted
to keep the SpO2 within the target range. However, due to clinical instability
and the limited time nurses have to adjust the amount of oxygen, preterm
infants only spent approximately 50% of the time within the SpO2 target range.
Recent studies have shown that the automatic fractional inspired oxygen (FiO2)
function of the AVEA ventilator is more capable of maintaining preterm infants
within preset saturation ranges than manual adjustment. However, it is unknown
to what extent narrowing the SpO2 target range during automated control will
result in a tighter control of the SpO2.
Study objective
To assess the optimal target range of the automatic FiO2 function by
maintaining the same mean, and narrowing the upper and lower limits of the
target range.
Study design
Randomized controlled cross-over trial. In order to find the optimal target
range of the automatic FiO2 function of the AVEA ventilator, the target ranges
will be set at random order to 86-94%, 88-92%, and 89-91%, respectively for 24
hours each.
Study burden and risks
Burden: There is no additional burden for the patient. All infants
participating in the study are subjected to routine neonatal intensive care and
are already treated with the AVEA ventilator. The CLIO2 function can be switch
on and adjusted without disturbing the patient. As part of standard care,
cardio-respiratory and oxygenation status will be monitored continuously. This
study does not require extra investigations or interventions.
Benefit and risks: Previous studies have shown that using automatic FiO2
function to keep the patient within preset saturation ranges is feasible and
safe. This study will evaluate the efficacy of such a tool narrowing those
target ranges. Avoiding hyperoxemia and hypoxia by tight control of the
saturation ranges could be a potential benefit for the included patients, as
there is now a considerable body of evidence showing that both hypoxia and
hyperoxemia can damage multiple organ systems in the preterm infant.
There are no additional known risks to the infant other than those experienced
routinely by the premature infants who require supplemental oxygen while in the
newborn intensive care nursery.
There are specific alarms and user alerts built in the automatic FiO2 function
to improve patient safety in addition to the standard alarms of the pulse
oximeter. These alarms will alert the routine caregivers of conditions that
require assessment and possible intervention.
Group relatedness: Respiratory instability for which supplemental oxygen is
required is a complication occurring exclusively in preterm infants. Any
intervention aiming to reduce the risk of hyperoxemia or hypoxia therefore
needs to be studied in this specific population at risk.
Meibergdreef 9
Amsterdam 1105 AZ
NL
Meibergdreef 9
Amsterdam 1105 AZ
NL
Listed location countries
Age
Inclusion criteria
Born with a gestational age between 24-32 weeks
Birth weight between 0.4 and 2 kg
Recieving NCPAP or NIPPV with supplemental oxygen for more than 18 hours per day
Exclusion criteria
Lack of parenteral informed consent
Congenital malformation
Requiring vasopressors 48 hours before enrollment
Culture proven infection 72 hours before enrollment
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
CCMO | NL45598.018.13 |